Withdrawal Therapy for Breast Cancer
Author Information
Author(s): Amit Agrawal, John F. Robertson, KL Cheung
Primary Institution: University of Nottingham, Royal Derby Hospital
Hypothesis
Does withdrawal therapy from endocrine agents provide clinical benefits in breast cancer patients?
Conclusion
Withdrawal therapy appears to produce sustained clinical benefit in a significant proportion of patients with breast cancer.
Supporting Evidence
- 58.8% of patients experienced clinical benefit from withdrawal therapy.
- The median duration of clinical benefit was over 10 months.
- Patients had previously undergone multiple lines of endocrine therapy.
Takeaway
This study shows that stopping certain cancer treatments can help some patients feel better, even after they have tried many other treatments.
Methodology
Retrospective review of breast cancer patients who received withdrawal therapy from endocrine agents.
Limitations
The study is limited by its small sample size and retrospective design.
Participant Demographics
Patients were elderly (age > 70 years) with estrogen receptor positive breast cancer.
Statistical Information
Confidence Interval
53.7-92.5
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website